PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of PT-141 is peak effects 15-30 minutes post-injection. This means dosing on-demand, 45 minutes before anticipated activity; maximum 8 doses per month is typical to maintain stable levels. The half-life directly affects how long PT-141 remains active and influences optimal injection timing.
What Is the Half-Life of PT-141?
The half-life of PT-141 is peak effects 15-30 minutes post-injection. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer PT-141 to maintain therapeutic blood levels.
What Does PT-141's Half-Life Mean for Dosing?
With a half-life of peak effects 15-30 minutes post-injection, PT-141 requires dosing on-demand, 45 minutes before anticipated activity; maximum 8 doses per month to maintain stable levels. The standard dosage of 1.75 mg per dose (FDA-approved) via subcutaneous self-injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, PT-141 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For PT-141, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject PT-141?
Optimal timing depends on your research goals. A half-life of peak effects 15-30 minutes post-injection means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (on-demand, 45 minutes before anticipated activity; maximum 8 doses per month) for more stable levels throughout the day.
How Does PT-141's Half-Life Compare to Similar Peptides?
PT-141 is a Melanocortin receptor agonist. Its half-life of peak effects 15-30 minutes post-injection positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Bottom Line: PT-141 Half-Life and Dosing
PT-141 has a half-life of peak effects 15-30 minutes post-injection, supporting the standard protocol of 1.75 mg per dose (FDA-approved) dosed on-demand, 45 minutes before anticipated activity; maximum 8 doses per month over on-demand acute dosing; no continuous cycle required.
Read our PT-141 dosage guide for complete protocol details.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Benefits
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.